# Inflammation-Driven Downregulation of CYP2E1 Is Associated with Attenuated Diethylnitrosamine (DEN)-Induced Hepatocarcinogenesis

**Authors:** Yoshihiro Tsuchiya, Yusuke Sotomaru, Akinori Kanai, Shin Maeda, Hideaki Kamata

PMC · DOI: 10.3390/cells15060546 · 2026-03-19

## TL;DR

Chronic liver inflammation reduces the risk of liver cancer by suppressing enzymes that activate carcinogens.

## Contribution

A new 'metabolic gatekeeping' model is proposed where inflammation limits chemical-induced liver cancer via downregulation of xenobiotic metabolism.

## Key findings

- Transgenic mice with chronic liver inflammation are resistant to DEN-induced hepatocarcinogenesis.
- Inflammation suppresses CYP2E1 and other xenobiotic-metabolizing enzymes, reducing DNA damage and p53 activation.
- Reduced HNF4α–PXR–CAR signaling and CYP2E1 activity blunt DEN bioactivation and tumor initiation.

## Abstract

What are the main findings?
Transgenic (Tg)-IKKβΔhep mice develop spontaneous chronic hepatitis and fibrosis yet are resistant to DEN-induced hepatocarcinogenesis.Chronic inflammatory signaling suppresses pericentral CYP2E1 and broadly down-regulates hepatic xenobiotic-metabolism programs.

Transgenic (Tg)-IKKβΔhep mice develop spontaneous chronic hepatitis and fibrosis yet are resistant to DEN-induced hepatocarcinogenesis.

Chronic inflammatory signaling suppresses pericentral CYP2E1 and broadly down-regulates hepatic xenobiotic-metabolism programs.

What are the implications of the main findings?
Attenuated HNF4α–PXR–CAR transcriptional output is associated with reduced DEN-triggered DNA-damage responses and p53 activation.These data support an inflammation-driven “metabolic gatekeeping” model in which chronic liver injury can constrain chemical tumor initiation by suppressing procarcinogen-metabolizing capacity.

Attenuated HNF4α–PXR–CAR transcriptional output is associated with reduced DEN-triggered DNA-damage responses and p53 activation.

These data support an inflammation-driven “metabolic gatekeeping” model in which chronic liver injury can constrain chemical tumor initiation by suppressing procarcinogen-metabolizing capacity.

Inflammation is widely viewed as a driver of hepatocellular carcinoma (HCC), yet inflammatory signaling also reshapes hepatic xenobiotic metabolism. Here, we established transgenic (Tg) IKKβΔhep mice (Tg-IKKβΔhep), which combine hepatocyte-specific IKKβ deletion with liver expression of a nuclear, kinase-inactive IKKβ mutant (NLS-IKKβKN). Tg-IKKβΔhep mice developed spontaneous chronic hepatitis and progressive fibrosis but were strikingly resistant to diethylnitrosamine (DEN)-induced hepatocarcinogenesis, with markedly reduced tumor multiplicity and total tumor burden. Despite persistent inflammatory injury, DEN-triggered oxidative DNA damage and p53 activation were markedly attenuated, compatible with reduced tumor initiation. Transcriptomic and biochemical analyses revealed broad repression of xenobiotic-metabolizing cytochrome P450 genes, including the pericentral enzyme CYP2E1, accompanied by reduced CYP2E1 protein abundance. This was associated with impaired HNF4α–PXR–CAR transcriptional output and reduced HNF4α occupancy at target promoters. Acute TNFα or IL-1β exposure recapitulated this repression, in part through reduced PGC-1α expression and decreased RNA polymerase II recruitment to target promoters. In parallel, pericentral xenobiotic metabolism was blunted, a change that could plausibly diminish DEN bioactivation and genotoxic stress. Together, these findings support a “metabolic gatekeeping” model in which chronic inflammation can constrain chemical hepatocarcinogenesis by attenuating carcinogen-metabolizing capacity.

## Linked entities

- **Genes:** CYP2E1 (cytochrome P450 family 2 subfamily E member 1) [NCBI Gene 1571], HNF4A (hepatocyte nuclear factor 4 alpha) [NCBI Gene 3172], NR1I2 (nuclear receptor subfamily 1 group I member 2) [NCBI Gene 8856], CASR (calcium sensing receptor) [NCBI Gene 846], IKBKB (inhibitor of nuclear factor kappa B kinase subunit beta) [NCBI Gene 3551], NR1I2 (nuclear receptor subfamily 1 group I member 2) [NCBI Gene 8856], PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891]
- **Proteins:** CYP2E1 (cytochrome P450 family 2 subfamily E member 1), HNF4A (hepatocyte nuclear factor 4 alpha), NR1I2 (nuclear receptor subfamily 1 group I member 2), CASR (calcium sensing receptor), TP53 (tumor protein p53), RNA polymerase II (DNA-directed RNA polymerase II subunit RPB7)
- **Chemicals:** diethylnitrosamine (PubChem CID 5921)
- **Diseases:** hepatocellular carcinoma (MONDO:0007256), chronic hepatitis (MONDO:0002251)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Nfkbia (nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha) [NCBI Gene 18035] {aka Nfkbi}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, Timp1 (tissue inhibitor of metalloproteinase 1) [NCBI Gene 21857] {aka Clgi, EPA, TIMP-1, TPA-S1, Timp}, Egfr (epidermal growth factor receptor) [NCBI Gene 13649] {aka 9030024J15Rik, Erbb, Errb1, Errp, Wa5, wa-2}, Ppig (peptidyl-prolyl isomerase G (cyclophilin G)) [NCBI Gene 228005] {aka B230312B02Rik, CYP, SRCyp}, H2ax (H2A.X variant histone) [NCBI Gene 15270] {aka H2A.X, H2afx, Hist5-2ax, gammaH2ax}, Jun (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 16476] {aka AP-1, Junc, c-jun}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, S100a8 (S100 calcium binding protein A8 (calgranulin A)) [NCBI Gene 20201] {aka 60B8Ag, B8Ag, CFAg, CP-10, Caga, MRP8}, Glul (glutamate-ammonia ligase) [NCBI Gene 14645] {aka GS, Glns}, Rela (Rela proto-oncogene, NFKB subunit) [NCBI Gene 19697] {aka p65, p65 NF-kappa B, p65 NFkB}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Ikbkg (inhibitor of kappaB kinase gamma) [NCBI Gene 16151] {aka 1110037D23Rik, IKK[g], NEMO}, Lcn2 (lipocalin 2) [NCBI Gene 16819] {aka 24p3, NRL, Sip24}, Gpt (glutamic pyruvic transaminase, soluble) [NCBI Gene 76282] {aka 1300007J06Rik, 2310022B03Rik, ALT, ALT1, Gpt-1, Gpt1}, Cyp2c54 (cytochrome P450, family 2, subfamily c, polypeptide 54) [NCBI Gene 404195] {aka EG404195}, Ppargc1a (peroxisome proliferative activated receptor, gamma, coactivator 1 alpha) [NCBI Gene 19017] {aka A830037N07Rik, Gm11133, PGC-1, PPARGC-1-alpha, Pgc-1alpha, Pgc1}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Trp53-ps (transformation related protein 53, pseudogene) [NCBI Gene 22060], S100a9 (S100 calcium binding protein A9 (calgranulin B)) [NCBI Gene 20202] {aka 60B8Ag, BEE22, Cagb, GAGB, L1Ag, MRP14}, Re (rex) [NCBI Gene 109540] {aka Den, Ri, denuded, riccioli}, Nr1i3 (nuclear receptor subfamily 1, group I, member 3) [NCBI Gene 12355] {aka CAR, CAR-beta, Care2, ESTM32, MB67}, Lmnb1 (lamin B1) [NCBI Gene 16906], Cpe (carboxypeptidase E) [NCBI Gene 12876] {aka CPH, Cph-1, Cph1, NF-alpha1, fat}, Cd44 (CD44 antigen) [NCBI Gene 12505] {aka HERMES, Ly-24, Pgp-1}, Afp (alpha fetoprotein) [NCBI Gene 11576], Cyp8b1 (cytochrome P450, family 8, subfamily b, polypeptide 1) [NCBI Gene 13124], Cdkn1a (cyclin dependent kinase inhibitor 1A) [NCBI Gene 12575] {aka CAP20, CDKI, CIP1, Cdkn1, P21, SDI1}, Nr1i2 (nuclear receptor subfamily 1, group I, member 2) [NCBI Gene 18171] {aka PXR, PXR.1, PXR.2, PXR1, SXR, mPXR}, Hnf4a (hepatic nuclear factor 4, alpha) [NCBI Gene 15378] {aka HNF-4, Hnf4, Hnf4alpha, MODY1, Nr2a1, TCF-14}, Cyp7a1 (cytochrome P450, family 7, subfamily a, polypeptide 1) [NCBI Gene 13122] {aka CYPVII, CYPVIIc}, Cyp2e1 (cytochrome P450, family 2, subfamily e, polypeptide 1) [NCBI Gene 25086] {aka Cyp2e}, Acta2 (actin alpha 2, smooth muscle, aorta) [NCBI Gene 11475] {aka 0610041G09Rik, Actvs, SMAalpha, SMalphaA, a-SMA, alphaSMA}, Saa (serum amyloid A cluster) [NCBI Gene 111345], Adgre1 (adhesion G protein-coupled receptor E1) [NCBI Gene 13733] {aka DD7A5-7, EGF-TM7, Emr1, F4/80, Gpf480, Ly71}, Ppara (peroxisome proliferator activated receptor alpha) [NCBI Gene 19013] {aka 4933429D07Rik, Nr1c1, PPAR-alpha, PPARalpha, Ppar}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Cyp21a1 (cytochrome P450, family 21, subfamily a, polypeptide 1) [NCBI Gene 13079] {aka 21-OH, 21OH, 21OHA, 21OHB, CYP21OH-A, Cyp21}, Cyp2e1 (cytochrome P450, family 2, subfamily e, polypeptide 1) [NCBI Gene 13106] {aka CYPIIE1, Cyp2e}, Mki67 (antigen identified by monoclonal antibody Ki 67) [NCBI Gene 17345] {aka D630048A14Rik, Ki-67, Ki67}, Ikbkb (inhibitor of kappaB kinase beta) [NCBI Gene 16150] {aka IKK-2, IKK-B, IKK-beta, IKK2, IKK[b], IKKbeta}, Bax (BCL2-associated X protein) [NCBI Gene 12028], Alb (albumin) [NCBI Gene 11657] {aka Alb-1, Alb1, BCL001, BCL002, BPL001}
- **Diseases:** chemical (MESH:D019966), HCC (MESH:D006528), tumorigenic (MESH:D002471), pain (MESH:D010146), impaired grooming (MESH:D060825), hepatocyte injury (MESH:D014947), lethargy (MESH:D053609), carcinogenesis (MESH:D063646), Chronic liver injury (MESH:D056487), death (MESH:D003643), DNA Damage (MESH:D004266), liver tumors (MESH:D008113), Liver Injury (MESH:D017093), CCl4 injury (MESH:D002252), liver disease (MESH:D008107), growth retardation (MESH:D006130), Inflammation (MESH:D007249), MASH (MESH:D005234), GS (MESH:C536832), carcinogenic (MESH:D011230), hepatitis virus infection (MESH:D006525), hepatic injury (MESH:D056486), alcohol-associated liver disease (MESH:D008108), dislocation (MESH:D004204), Tumor (MESH:D009369), weight loss (MESH:D015431), Fibrosis (MESH:D005355), tissue injury (MESH:D017695), Chronic Hepatitis (MESH:D006521), chronic (MESH:D002908)
- **Chemicals:** DEN (MESH:D004052), FITC (MESH:D016650), DAB (MESH:C000469), SDS (MESH:D012967), DAPI (MESH:C007293), alcohol (MESH:D000438), xylene (MESH:D014992), EDTA (MESH:D004492), TRIzol (MESH:C411644), glycerol (MESH:D005990), Azan (-), O6-ethylguanine (MESH:C007673), citrate (MESH:D019343), PVDF (MESH:C024865), isoamyl alcohol (MESH:C029683), chloroform (MESH:D002725), ethanol (MESH:D000431), Triton X-100 (MESH:D017830), chlormethiazole (MESH:D002719), hematoxylin (MESH:D006416), 8-OHdG (MESH:D000080242), Tween 20 (MESH:D011136), CO2 (MESH:D002245), poly(dI-dC) (MESH:C031156), CCl4 (MESH:D002251), NaCl (MESH:D012965), glycine (MESH:D005998), Fluorescein (MESH:D019793), polyacrylamide (MESH:C016679), water (MESH:D014867), DTT (MESH:D004229), paraffin (MESH:D010232), TBE buffer (MESH:C069591), formaldehyde (MESH:D005557), phenol (MESH:D019800), PBS (MESH:D007854), bile acid (MESH:D001647), H&amp;E (MESH:D006371), corn oil (MESH:D003314)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Mutations:** K44A
- **Cell lines:** C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW), /6J — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_W797)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025445/full.md

---
Source: https://tomesphere.com/paper/PMC13025445